We we heard today was astounding news.
“All patients have now been treated in the Phase II trial of ICX-TRC, our hair regeneration product, and the results so far are promising.”
This means that phase 2 is close to completion since everyone has been treated. Remember that today’s report was upto 31st dec 2007. We are 12 weeks past that stage now."These data are consistent with the earlier data reported last September and the hypothesis that new hair production is improved by pre-stimulation of the scalp, leading to an interaction between the injected cells and the resident hair producing cells."
They tried a few variations but I think they’ve found the winning formula ie “pre - stimulation”
“We made considerable progress in 2007 in all of our programmes, generating clinical data across the product portfolio in a greatly expanded patient base. We are seeing very encouraging efficacy which gives us great confidence in the application of our technology and our commercial prospects.”
Their products are very close the market.
“As a company we have achieved much in a short time and with relatively modest cash resources.”
The fact that they want to complete their trials after phase II is down to cash not results.
“The barrier to commercial success for ICX-TRC is relatively low, being the ability to increase hair count in transplanted or thinning areas.”
There is no risk of getting to the market. There are so many people who want to use TRC.
Essentially what today’s report showed that TRC will follow a similar commercial path to vavaleta i’e no need for phase 3.
Bosley already has the set up so it makes sense for them to sell TRC.